EXPEDITION MEDICINES

What this means for you

Not registered yet, but its 04 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99067174

Mark type

Stylized text

Filed

04 Mar 2025

Published for opposition

16 Sept 2025

Attorney of record

Christina M. Licursi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders
• Class 009 — Scientific and electric apparatus: Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics
• Class 042 — Scientific and technological services: Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; scientific research, namely, research and analysis services for the design and characterization of chemical and biologic therapeutic products; research services in the fields of genomic, transcriptomic, and proteomic analysis; genomic and proteomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; DNA analysis and sequencing services for scientific and research purposes; research, development and consultancy in the field of genomics and proteomics; medical research, namely, compiling data for research purposes in the field of genomics and proteomics; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics

Owner

• Expedition Medicines, Inc., Cambridge, MA, US
• Expedition Medicines, Inc., Cambridge, MA, US

Prosecution history

• 12 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 11 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
• 11 Dec 2025 — TEAS REQUEST TO DIVIDE RECEIVED
• 11 Dec 2025 — SOU EXTENSION 1 GRANTED
• 11 Dec 2025 — SOU EXTENSION 1 FILED
• 11 Dec 2025 — SOU TEAS EXTENSION RECEIVED
• 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 16 Sept 2025 — PUBLISHED FOR OPPOSITION
• 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 20 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 19 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 19 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 19 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 08 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED